2. Apoptosis Metabolic Enzyme/Protease
  3. Glutathione Peroxidase Ferroptosis
  4. GPX4-IN-9

GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets GPX4 under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

GPX4-IN-9

GPX4-IN-9 構造式

CAS 番号 : 3032746-99-6

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 482 在庫あり
Solution
10 mM * 1 mL in DMSO USD 482 在庫あり
Solid
5 mg $465 在庫あり
10 mg $750 在庫あり
25 mg $1500 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

GPX4-IN-9 関連抗体

Top Publications Citing Use of Products

Glutathione Peroxidase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
GPX1 GPX4

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets GPX4 under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research[1].

IC50 & Target

GPX4

 

Cellular Effect
Cell Line Type Value Description References
ASPC1 IC50
0.022 μM
Compound: A16
Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
ASPC1 IC50
14 nM
Compound: A16
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
ASPC1 IC50
26 nM
Compound: A16
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
[PMID: 38265413]
ASPC1 IC50
29 nM
Compound: A16
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs followed by compound washout by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs followed by compound washout by CCK-8 assay
[PMID: 38265413]
ASPC1 IC50
33 nM
Compound: A16
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs followed by compound washout by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs followed by compound washout by CCK-8 assay
[PMID: 38265413]
ASPC1 IC50
37 nM
Compound: A16
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 38265413]
ASPC1 IC50
62 nM
Compound: A16
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs followed by compound washout by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs followed by compound washout by CCK-8 assay
[PMID: 38265413]
BXPC-3 IC50
0.02 μM
Compound: A16
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
CFPAC-1 IC50
0.02 μM
Compound: A16
Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
HCT-116 IC50
> 10 nM
Compound: A16
Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
HPAF-II IC50
0.02 μM
Compound: A16
Antiproliferative activity against human HPAF-II cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HPAF-II cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
MIA PaCa-2 IC50
0.02 μM
Compound: A16
Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
NCI-H522 IC50
3 nM
Compound: A16
Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
PANC-1 IC50
0.02 μM
Compound: A16
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
SW1990 IC50
0.02 μM
Compound: A16
Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 38265413]
分子量

471.59

分子式

C26H21N3O2S2
CAS 番号
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=S(C(C=C1)=CC=C1CN(C2=CC=C(C=C2)C3=NC4=C(S3)C=CC=C4)CC#C)(N(C#C)C)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

DMSO : 50 mg/mL (106.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1205 mL 10.6024 mL 21.2049 mL
5 mM 0.4241 mL 2.1205 mL 4.2410 mL
10 mM 0.2120 mL 1.0602 mL 2.1205 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1205 mL 10.6024 mL 21.2049 mL 53.0122 mL
5 mM 0.4241 mL 2.1205 mL 4.2410 mL 10.6024 mL
10 mM 0.2120 mL 1.0602 mL 2.1205 mL 5.3012 mL
15 mM 0.1414 mL 0.7068 mL 1.4137 mL 3.5341 mL
20 mM 0.1060 mL 0.5301 mL 1.0602 mL 2.6506 mL
25 mM 0.0848 mL 0.4241 mL 0.8482 mL 2.1205 mL
30 mM 0.0707 mL 0.3534 mL 0.7068 mL 1.7671 mL
40 mM 0.0530 mL 0.2651 mL 0.5301 mL 1.3253 mL
50 mM 0.0424 mL 0.2120 mL 0.4241 mL 1.0602 mL
60 mM 0.0353 mL 0.1767 mL 0.3534 mL 0.8835 mL
80 mM 0.0265 mL 0.1325 mL 0.2651 mL 0.6627 mL
100 mM 0.0212 mL 0.1060 mL 0.2120 mL 0.5301 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

GPX4-IN-9 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GPX4-IN-93032746-99-6Glutathione PeroxidaseFerroptosispancreatic cancerferroptosisAsPC-1CFPAC-1PANC1BXPC-3MIA PaCa-2hpf – iiSW-1990NCI-H522Inhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
GPX4-IN-9
製品番号:
HY-157762
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.